{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:58:36Z","timestamp":1760057916335,"version":"build-2065373602"},"reference-count":39,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Kyowa Kirin International"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Objective: The aim of the NALOPOOL project was to assess the efficacy and safety of naloxegol in patients with cancer pain who exhibited opioid-induced constipation (OIC) and were treated under real-world conditions. Methods: We pooled individual patient data from three multicenter observational studies conducted with naloxegol in patients with cancer who exhibited OIC and were prescribed naloxegol under real-world conditions. Efficacy outcomes were evaluated after 4 weeks of treatment. All analyses were performed via a visit-wise approach. Heterogeneity was assessed via Cochran\u2019s Q-test or Levene\u2019s test. Results: Spontaneous bowel movements (SBM) response (\u22653 SBM per week and an increase of \u22651 from baseline; three studies) was reported in 223 of 314 evaluable patients (71%, 95% CI 66\u201376); clinically relevant improvement in the Patient Assessment of Constipation Quality-of-Life Questionnaire (&gt;0.5 points; three studies) occurred in 179 of 299 evaluable patients (60%, 95% CI 56\u201374) and in the Patient Assessment of Constipation Symptoms (&gt;0.5 points; two studies) was reported in 131 of 190 evaluable patients (69%, 95% CI 62\u201376); and clinically relevant improvement in the Bowel Function Index (score \u2265 12 points at the endpoint; two studies;) was reported in 133 of 195 evaluable patients (68%, 95% CI 62\u201375). No significant heterogeneity was found for any efficacy outcome. The pooled proportion of patients who discontinued the drug owing to adverse reactions was 6.1% (95% CI 3.8% to 8.4%). Conclusions: Our results support the use of naloxegol for the management of OIC in patients with cancer pain who do not respond to laxative treatment.<\/jats:p>","DOI":"10.3390\/cancers17050865","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:41:51Z","timestamp":1741066911000},"page":"865","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Naloxegol for the Treatment of Opioid-Induced Constipation in Patients with Cancer Pain: A Pooled Analysis of Real-World Data"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5591-3489","authenticated-orcid":false,"given":"Jean-Marc","family":"Sabat\u00e9","sequence":"first","affiliation":[{"name":"Gastroenterology and Gastrointestinal Oncology, H\u00f4pital Avicenne, AP-HP, Sorbonne University, 93000 Bobigny, France"},{"name":"INSERM U987, Pathophysiology and Clinical Pharmacology of Pain, 92012 Boulogne Billancourt, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Beato-Zambrano","sequence":"additional","affiliation":[{"name":"Medical Oncology, Hospital Universitario Virgen Macarena, 41009 Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-1144","authenticated-orcid":false,"given":"Manuel","family":"Cobo","sequence":"additional","affiliation":[{"name":"Medical Oncology, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga-Plataforma BIONAND (IBIMA-BIONAND), Hospital Regional Universitario Malaga, 29010 Malaga, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3612-5388","authenticated-orcid":false,"given":"Antoine","family":"Lemaire","sequence":"additional","affiliation":[{"name":"Oncology & Medical Specialties Department, Valenciennes General Hospital, 59300 Valenciennes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Montesarchio","sequence":"additional","affiliation":[{"name":"Pneumology and Oncology, A.O.R.N. dei Colli-Monaldi Hospital, 80131 Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Serna-Montros","sequence":"additional","affiliation":[{"name":"Palliative Care\/Medical Oncology Vhio, Hospital Campus Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafik","family":"Namane","sequence":"additional","affiliation":[{"name":"Laboratoires Gr\u00fcnenthal, 92800 Puteaux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Mart\u00edn Baccarelli","sequence":"additional","affiliation":[{"name":"Data Management & Biostatistics Department, APICES, Pinto, 28320 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rico-Villademoros","sequence":"additional","affiliation":[{"name":"Medical Department, APICES, Pinto, 28320 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11864-019-0686-6","article-title":"Opioid-induced constipation in oncological patients: New strategies of management","volume":"20","author":"Echaburu","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1526-4637.2008.00495.x","article-title":"The prevalence, severity, and impact of opioid-induced bowel dysfunction: Results of a US and European patient survey (PROBE 1)","volume":"10","author":"Bell","year":"2009","journal-title":"Pain Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/AJP.0000000000000852","article-title":"Opioid-induced constipation: A review of health-related quality of life, patient burden, practical clinical considerations, and the impact of peripherally acting \u03bc-opioid receptor antagonists","volume":"36","author":"Argoff","year":"2020","journal-title":"Clin. J. Pain"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5055\/jom.2009.0014","article-title":"Opioid-induced constipation negatively impacts pain management, productivity, and health-related quality of life: Findings from the National Health and Wellness Survey","volume":"5","author":"Bell","year":"2009","journal-title":"J. Opioid Manag."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2147\/JPR.S318564","article-title":"Common clinical practice for opioid-induced constipation: A physician survey","volume":"14","author":"Coluzzi","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40122-020-00195-z","article-title":"What to do and what not to do in the management of opioid-induced constipation: A choosing Wisely report","volume":"9","author":"Alvaro","year":"2020","journal-title":"Pain Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/pm\/pny151","article-title":"Analysis of patient-provider interactions regarding the burden and treatment of opioid-induced constipation in adults with chronic noncancer pain","volume":"20","author":"Vallerand","year":"2019","journal-title":"Pain Med."},{"key":"ref_9","first-page":"236","article-title":"The burden of opioid-induced constipation: Discordance between patient and health care provider reports","volume":"22","author":"LoCasale","year":"2016","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S1067","DOI":"10.1016\/j.annonc.2020.08.1518","article-title":"1871P Overcoming barriers in opioid-induced constipation management","volume":"31","author":"Cordellat","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1053\/j.gastro.2018.07.016","article-title":"American gastroenterological association institute guideline on the medical management of opioid-induced constipation","volume":"156","author":"Crockett","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_12","first-page":"1932","article-title":"Laxatives do not improve symptoms of opioid-induced constipation: Results of a patient survey","volume":"18","author":"Emmanuel","year":"2017","journal-title":"Pain Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.sjpain.2015.12.007","article-title":"Opioid-induced constipation, use of laxatives, and health-related quality of life","volume":"11","author":"Christensen","year":"2016","journal-title":"Scand. J. Pain"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/pme.12724","article-title":"Opioid-induced constipation among patients with chronic noncancer pain in the United States, Canada, Germany, and the United Kingdom: Laxative use, response, and symptom burden over time","volume":"16","author":"Coyne","year":"2015","journal-title":"Pain Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2147\/DDDT.S221278","article-title":"The use of peripheral \u03bc-opioid receptor antagonists (PAMORA) in the management of opioid-induced constipation: An update on their efficacy and safety","volume":"14","author":"Pergolizzi","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0897190017732263","article-title":"Peripherally acting \u03bc-opioid receptor antagonists for the treatment of opioid-related side effects: Mechanism of action and clinical implications","volume":"31","author":"Streicher","year":"2018","journal-title":"J. Pharm. Pract."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1310246","article-title":"Naloxegol for opioid-induced constipation in patients with noncancer pain","volume":"370","author":"Chey","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/apt.12899","article-title":"Randomised clinical trial: The long-term safety and tolerability of naloxegol in patients with pain and opioid-induced constipation","volume":"40","author":"Webster","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/bjc.2013.725","article-title":"Randomised controlled trials and population-based observational research: Partners in the evolution of medical evidence","volume":"110","author":"Booth","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1016\/j.jpainsymman.2018.09.024","article-title":"Challenges in recruiting patients to a controlled feasibility study of a drug for opioid-induced constipation: Lessons from the population with advanced cancer","volume":"57","author":"Bull","year":"2019","journal-title":"J. Pain Symptom Manag."},{"key":"ref_21","first-page":"8","article-title":"Real-life data: A growing need","volume":"13","author":"Annemans","year":"2007","journal-title":"ISPOR Connect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmjspcare-2020-002249","article-title":"Efficacy of naloxegol on symptoms and quality of life related to opioid-induced constipation in patients with cancer: A 3-month follow-up analysis","volume":"11","author":"Dols","year":"2021","journal-title":"BMJ Support. Palliat. Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"7577","DOI":"10.1007\/s00520-021-06299-2","article-title":"Effectiveness of naloxegol in patients with cancer pain suffering from opioid-induced constipation","volume":"29","author":"Lemaire","year":"2021","journal-title":"Support. Care Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Davies, A., Cinieri, S., Dupoiron, D., Fernandez, S.E., Leclerc, J., Montesarchio, V., Mystakidou, K., Serna, J., and Tack, J. On Behalf of the NACASY Study Group (2022). A prospective, real-world, multinational study of naloxegol for patients with cancer pain diagnosed with opioid-induced constipation-the NACASY study. Cancers, 14.","DOI":"10.3390\/cancers14051128"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: Disorders of gut-brain interaction","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1080\/00365520510012208","article-title":"Development and validation of the patient assessment of constipation quality of life questionnaire","volume":"40","author":"Marquis","year":"2005","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/003655299750025327","article-title":"Psychometric validation of a constipation symptom assessment questionnaire","volume":"34","author":"Frank","year":"1999","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejpain.2005.03.008","article-title":"Validation of the PAC-SYM questionnaire for opioid-induced constipation in patients with chronic low back pain","volume":"10","author":"Slappendel","year":"2006","journal-title":"Eur. J. Pain"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1185\/03007995.2012.657301","article-title":"The bowel function index: A new validated scale for assessing opioid-induced constipation","volume":"28","year":"2012","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/00365529709011203","article-title":"Stool form scale as a useful guide to intestinal transit time","volume":"32","author":"Lewis","year":"1997","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Hiruta, E., Fujita, Y., Imai, H., Masuno, T., Yamazaki, S., Tanaka, H., Kamiya, T., Ito, M., Takei, S., and Matsuura, M. (2021). Real-world patient characteristics and treatment patterns of naldemedine for the treatment of opioid-induced constipation in patients with cancer: A multicenter retrospective chart review study. Medicina, 57.","DOI":"10.3390\/medicina57111233"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"697","DOI":"10.21037\/apm-22-1130","article-title":"Efficacy and safety of naldemedine treatment for opioid-induced constipation in gastrointestinal cancer: A retrospective analysis","volume":"12","author":"Nishiba","year":"2023","journal-title":"Ann. Palliat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3859","DOI":"10.1200\/JCO.2017.73.0853","article-title":"Randomized phase III and extension studies of naldemedine in patients with opioid-induced constipation and cancer","volume":"35","author":"Katakami","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.18632\/aging.202526","article-title":"The impact of visceral obesity on chronic constipation, inflammation, immune function and cognitive function in patients with inflammatory bowel disease","volume":"13","author":"Wan","year":"2021","journal-title":"Aging"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Nagata, N., Sakamoto, K., Arai, T., Niikura, R., Shimbo, T., Shinozaki, M., Ihana, N., Sekine, K., Okubo, H., and Watanabe, K. (2015). Effect of body mass index and intra-abdominal fat measured by computed tomography on the risk of bowel symptoms. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123993"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/pme.12937","article-title":"Consensus recommendations on initiating prescription therapies for opioid-induced constipation","volume":"16","author":"Argoff","year":"2015","journal-title":"Pain Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1177\/2050640618786145","article-title":"The patient burden of opioid-induced constipation: New insights from a large, multinational survey in five European countries","volume":"6","author":"Andresen","year":"2018","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_38","unstructured":"World Health Organization (2024, July 08). Palliative Care. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/palliative-care."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ostan, R., Gambino, G., Malavasi, I., Ronga, G., Solipaca, M., Spunghi, M., Varani, S., Pannuti, R., and Ruggeri, E. (2021). Can naloxegol therapy improve quality of life in patients with advanced cancer?. Cancers, 13.","DOI":"10.3390\/cancers13225736"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/865\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:46:07Z","timestamp":1760028367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/5\/865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["cancers17050865"],"URL":"https:\/\/doi.org\/10.3390\/cancers17050865","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}